Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.

In this review, cosmetic practices such as non-ablative lasers, autologous fat injections, and oral isotretinoin may help alleviate certain symptoms of frontal fibrosing alopecia, while treatments like deep chemical peels and ablative laser therapies are contraindicated due to potential scarring risks.

In this study, using a novel topical androgen receptor suppressor, fluridil, significantly increased the percentage of growing hairs in males with androgenetic alopecia without systemic absorption or adverse side effects.

This study found that the newly developed microarray patches for intradermal delivery of finasteride showed high drug content and significantly improved skin deposition compared to existing methods.

This study investigated a unique frontal fibrosing alopecia-like presentation of alopecia areata, finding that patients experienced an insidious, chronic course with limited scalp hair regrowth, and showed a lower response to systemic corticosteroids compared to patchy alopecia areata.

This study concluded that the Free Androgen Index (FAI) could serve as a reliable biomarker for hyperandrogenism in women with androgenetic alopecia, showing more predictive value than testosterone or SHBG alone.

This study identified a heterozygous de novo mutation in the ODC1 gene causing a new disorder characterized by overgrowth and developmental delay, and suggests that DFMO treatment may help manage elevated ODC activity and putrescine levels.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

This study found that retinoic acid and a retinol complex formulation showed different permeation and compound localization in a skin equivalent model, with unique lipid changes observed with only the retinol formulation.

Allergic contact dermatitis may promote hair growth by activating hair follicle stem cells.

The researchers reported that in a mouse model of alopecia areata, tofacitinib treatment influenced disease progression by modulating CD8⁺ T cell infiltration through the linoleic acid metabolism and magnesium ion pathway, offering insights into potential treatment approaches.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

In this study, researchers found that ligand homodimerization controls the receptor binding specificity of the FGF9 subfamily, preventing off-target activation of FGFR "b" isoforms.

In a murine model of androgenetic alopecia, this study found that the newly designed IGF-1 biomimetic peptide Ac-GFFY-IGF led to faster and superior hair regrowth compared to minoxidil, suggesting potential for improved human therapies.

This hypothesis article explores frontal fibrosing alopecia as a potential autoimmune condition and calls for future research to investigate this possibility, but reports no new clinical results.

Finasteride may help treat frontal fibrosing alopecia, but more research is needed.

This study reports on a new semantic annotation approach used to identify substances in MEDLINE abstracts responsible for adverse drug reactions, with promising performance shown by a prototype system.

This report analyzed an FDA adverse event database and aimed to evaluate and describe post-finasteride syndrome potentially related to dutasteride, but it does not report new clinical findings.

Adding a cosmetic gel with caffeine, taurine, and growth factors to standard hair loss treatments could improve results.

This study found that tofacitinib may inhibit CD8+ T cell infiltration in alopecia areata by affecting the linoleic acid metabolism-Mg2+ pathway in a sodium sulfide-induced mouse model, highlighting new insights for clinical diagnosis and treatment strategies.

This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.

In this clinical experience, treating frontal fibrosing alopecia with oral finasteride, hydroxychloroquine, tacrolimus, and excimer laser was associated with optimal results in patients with active inflammation.

This meta-analysis suggests a significant association between the use of facial sunscreen and moisturizer and frontal fibrosing alopecia, while finding no significant relationship with hair products or treatments.

Frontal fibrosing alopecia may be caused by an autoimmune reaction and hormonal imbalance.

In this study, patients with specific skin and scalp conditions, including eczematous lesions, showed significant improvement after two weeks of oral tofacitinib treatment, as evidenced by changes in the trunk lesions.

This paper highlights advances in Developmental Dynamics, noting how epoa-deficient zebrafish can model Diamond-Blackfan anemia like disorders for drug screening, Alx4 mouse models offer insights into craniofacial development, and mTORC1 signaling is crucial for retinal development.